Praxis Precision Medicines

colorful brain art model
Biotech

Praxis sees success in ph. 2 seizure trial, setting up FDA push

Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for its sodium channel inhibitor.
James Waldron Dec 5, 2025 10:00am
An arrow incrementally going up stairs before pointing straight up Blue background

Praxis plots path to FDA after phase 3 wins in essential tremor

Oct 16, 2025 11:48am
White arrow on a road pointing to the rising sun

Praxis' drug reduces seizures but sees 23% discontinuation rate

Aug 4, 2025 10:22am
success failure signposts

Praxis moves ahead despite phase 3 tremor trial futility finding

Feb 28, 2025 9:11am
brain amyloid alzheimers strings detailed web complicated thought

Praxis epilepsy drug reduces seizures in phase 2 trial

Sep 3, 2024 10:21am
graphic of the brain and the electrical signals that make it up

Praxis' epilepsy drug hits in phase 2, sparking stock rise

Mar 26, 2024 10:24am